Human Papillomavirus and Genital Warts: A Review of the Evidence for the 2015 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines
- 23 November 2015
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 61 (suppl 8), S849-S855
- https://doi.org/10.1093/cid/civ813
Abstract
To provide updates for the 2015 Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines on human papillomavirus (HPV) and anogenital warts (AGWs), a review of the literature was conducted in key topic areas: (1) epidemiology and burden of disease; (2) transmission and natural history; (3) diagnosis and management of AGWs; (4) occupational exposure of healthcare workers; (5) anal cancer screening among men who have sex with men (MSM); and (6) HPV vaccine recommendations. Most sexually active persons will have detectable HPV at least once in their lifetime; 14 million persons are infected annually, and 79 million persons have prevalent infection. HPV is transmitted frequently between partners; more frequent transmission has been reported from females to males than from males to females. A new formulation of imiquimod (3.75% cream) is recommended for AGW treatment. Appropriate infection control, including performing laser or electrocautery in ventilated rooms using standard precautions, is recommended to prevent possible transmission to healthcare workers who treat anogenital warts, oral warts, and anogenital intraepithelial neoplasias (eg, cervical intraepithelial neoplasia). Data are insufficient to recommend routine anal cancer screening with anal cytology in persons living with human immunodeficiency virus (HIV)/AIDS or HIV-negative MSM. An annual digital anorectal examination may be useful for early detection of anal cancer in these populations. HPV vaccine is recommended routinely for 11- or 12-year-olds, as well as for young men through age 21 years and young women through age 26 years who have not previously been vaccinated. HPV vaccine is also recommended for MSM, people living with HIV/AIDS, and immunocompromised persons through age 26 years.Funding Information
- CDC
This publication has 58 references indexed in Scilit:
- Systematic review of the incidence and prevalence of genital wartsBMC Infectious Diseases, 2013
- Annual Report to the Nation on the Status of Cancer, 1975–2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)–Associated Cancers and HPV Vaccination Coverage LevelsJNCI Journal of the National Cancer Institute, 2013
- HPV Vaccine against Anal HPV Infection and Anal Intraepithelial NeoplasiaThe New England Journal of Medicine, 2011
- Incidence and Human Papillomavirus (HPV) Type Distribution of Genital Warts in a Multinational Cohort of Men: The HPV in Men StudyThe Journal of Infectious Diseases, 2011
- Genital Transmission of Human Papillomavirus in Recently Formed Heterosexual CouplesThe Journal of Infectious Diseases, 2011
- Genital Warts and Vulvar Intraepithelial NeoplasiaObstetrics & Gynecology, 2011
- Comparative Accuracy of Anal and Cervical Cytology in Screening for Moderate to Severe Dysplasia by Magnification Guided Punch Biopsy: A Meta-AnalysisPLOS ONE, 2011
- Imiquimod 3.75% Cream Applied Daily to Treat Anogenital Warts: Combined Results from Women in Two Randomized, Placebo-Controlled StudiesInfectious Diseases in Obstetrics and Gynecology, 2011
- Early Natural History of Incident, Type-Specific Human Papillomavirus Infections in Newly Sexually Active Young WomenCancer Epidemiology, Biomarkers & Prevention, 2011
- Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort studyThe Lancet, 2011